Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia
Key result
Rosuvastatin reduces primary cardiovascular events in women comparable to benefits seen in men.
Why the study?
JUPITER demonstrated that rosuvastatin reduced cardiovascular events in women with a relative risk reduction similar to men, supported by meta-analysis of primary prevention statin trials.
Does rosuvastatin reduce cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia in primary prevention?
Population
Women with elevated high-sensitivity C-reactive protein or dyslipidemia in primary prevention
Comparison
Rosuvastatin versus placebo or no statin
Design
Randomized controlled trial
Authors
Discussion
Loading...
Member takes
Implication
May support rosuvastatin for primary prevention in women; extends male data but leaves open need for dedicated trials.
Structured PICO
Does rosuvastatin reduce cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia in primary prevention?
P
Population
Women with elevated high-sensitivity C-reactive protein or dyslipidemia in a primary prevention setting
I
Intervention
Rosuvastatin (statins)
O
Outcome
Cardiovascular (CVD) events
Rosuvastatin is effective for the primary prevention of cardiovascular events in women, providing a relative risk reduction comparable to that observed in men.
Cite This Study
Mora et al. (2010) studied this question. Rosuvastatin reduced cardiovascular events in women for primary prevention with a relative risk reduction similar to that in men.